SUBLICENSE AGREEMENTSublicense Agreement • August 30th, 2018 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • California
THIS SUBLICENSE Agreement (“Agreement”) is entered into on September 26, 2017 (the “Effective Date”) by and between BIOTIME, INC., a California corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“BioTime”), and AGEX THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“AgeX”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • August 30th, 2018 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Asset Purchase Agreement (this “Agreement”), dated as of March 21, 2018, is entered into between Ascendance Biotechnology, Inc., a Delaware corporation (the “Company”), and AgeX Therapeutics, Inc., a Delaware corporation (“Buyer”).
ASSET PURCHASE AGREEMENT By and between ESCAPE THERAPEUTICS, INC. and AGEX THERAPEUTICS, INC. dated as of August 13,Asset Purchase Agreement • August 30th, 2018 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • California
This Asset Purchase Agreement (this “Agreement”), dated as of August 13, 2018 is entered into between Escape Therapeutics, Inc., a California corporation (“Seller”) and AgeX Therapeutics, Inc., a Delaware corporation (“Buyer”).
